| Not yet recruiting | 2 | 41 | Europe | RVU120 (SEL120) | GCP-Service International West GmbH, Universitätsklinikum Leipzig, Saint-Louis Hospital, Paris, France, University of Florence, University of Salamanca, Medical University of Warsaw, Ryvu Therapeutics SA, European Myelodysplastic Neoplasms Cooperative Group | Low Risk Myelodysplastic Syndromes | 05/26 | 05/27 | | |
VEN-A-QUI, NCT04687761: Clinical Trial to Assess the Safety and Tolerability of the Combination of Low-dose Cytarabine or Azacitidine Plus Venetoclax and Quizartinib in Newly Diagnosed AML Patients Aged Equal or More Than 60 Years Old |
|
|
| Recruiting | 1/2 | 84 | Europe | Azacitidine, Venetoclax, Quizartinib, Cytarabine | PETHEMA Foundation | Leukemia, Myeloid, Acute, De Novo, Age More 60yr | 11/24 | 11/24 | | |
